MMJ Phytotech: Green light to start Phase 2 of clinical trial

Company News

by Jessica Amir

MMJ Phytotech Limited (ASX:MMJ) has announced it received international government approval to start Phase 2 of its clinical trial in treating multiple sclerosis (MS) patients.

The medical cannabis company’s Israeli-based subsidiary, received approval from the Ministry of Health and Helsinki (IRB of Sheba Clinical Site) to study 70 MS patients with their drug.

The study will take place at the MS Center, at the largest hospital in Israel, the Sheba Hospital.

The study will measure the safety and efficacy of Phytotech’s PTL201 capsules in treating debilitating MS symptoms

MMJ Phytotech says, the success of Phase 2 of the trial will be a major step toward the commercial development of its drug.

Shares in MMJ Phytotech Limited (ASX:MMJ) has last traded 2.56% lower to 38 cents.

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.